Phase 4 Heart Disease Trial, Recruiting (NCT06089577)

Phase 4 Heart Disease Trial, Recruiting NCT06089577 Sponsor: Federico II University Condition: Heart Disease

Printed from Voxsanity (voxsanity.com.au) — NCT06089577 — Data sourced from ClinicalTrials.gov. Verify directly with the trial site before attending. Not medical advice.

Back to Heart Disease

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

Adults (18 years of age or older)
People who have given written consent to participate in the study
People with chronic (long-term, stable) coronary artery disease — meaning heart artery problems that are not caused by a recent or emergency heart event
People who have not previously taken a type of blood-thinning medication known as P2Y12 inhibitors (examples include clopidogrel, ticagrelor, or prasugrel)
People scheduled for a planned, non-emergency procedure to open a blocked heart artery (called PCI), where the blockage is in a major artery, is a new lesion (not previously treated), and has been confirmed by a special pressure-based test (FFR) to be significantly affecting blood flow

Who may not be able to join:

People under the age of 18
People experiencing an acute (sudden or emergency) heart condition, such as a heart attack
People who are already taking P2Y12 inhibitor medications
People with severe heart failure where the heart's pumping ability is very low (confirmed by a heart function measurement below 30%)
People where the target artery blockage is nearly completely closed (more than 90% narrowed)

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.

Last synced 19 July 2026

Phase 4 trials study a drug that has already been approved, monitoring long-term safety and effectiveness in real-world use.

Contact this trial

Phone: +390817462235

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Voxsanity

Clinical trials and treatments, explained plainly · voxsanity.com.au

Date:

To: My Doctor

Re: Clinical trial enquiry

I am writing to enquire about the following clinical trial which may be relevant to my care:

Trial: NCT06089577

Sponsor: Federico II University

Phase: Phase 4

Status: Recruiting

Condition: Heart Disease

Trial contact: +390817462235

More information: https://clinicaltrials.gov/study/NCT06089577

Eligibility summary (AI generated)

Written by an AI model from ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

Adults (18 years of age or older)
People who have given written consent to participate in the study
People with chronic (long-term, stable) coronary artery disease — meaning heart artery problems that are not caused by a recent or emergency heart event
People who have not previously taken a type of blood-thinning medication known as P2Y12 inhibitors (examples include clopidogrel, ticagrelor, or prasugrel)
People scheduled for a planned, non-emergency procedure to open a blocked heart artery (called PCI), where the blockage is in a major artery, is a new lesion (not previously treated), and has been confirmed by a special pressure-based test (FFR) to be significantly affecting blood flow

Who may not be able to join:

People under the age of 18
People experiencing an acute (sudden or emergency) heart condition, such as a heart attack
People who are already taking P2Y12 inhibitor medications
People with severe heart failure where the heart's pumping ability is very low (confirmed by a heart function measurement below 30%)
People where the target artery blockage is nearly completely closed (more than 90% narrowed)

Important: Always verify eligibility with the trial site directly before applying.

Access in Australia: A treatment being studied in a clinical trial is generally not yet listed on the PBS. Where a medicine is not approved or not available through a trial, the TGA Special Access Scheme may allow a doctor to access unapproved therapeutic goods for individual patients. See voxsanity.com.au/sas-navigator/ for a plain English explainer.

This information was sourced from ClinicalTrials.gov via Voxsanity (data last synced 19 July 2026). It is not medical advice. Please verify the trial's current status directly with the trial site before acting.

Trial details

Status

Recruiting

Phase

Phase 4

Sponsor

Federico II University

Registry

ClinicalTrials.gov

Start date

1 November 2023

Est. completion

1 October 2025

Where this trial is recruiting

🇮🇹 Italy

Primary endpoints

Incidence of microvascular dysfunction

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 19 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov